Drugs / ECT-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03441958 | Mar 2018 → Oct 2023 | plasma cell myeloma | Ciusss de L'Est de l'Île de Montréal | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03913026 | Apr 2019 → Jun 2027 expected | hematopoietic and lymphoid cell neoplasm | Ciusss de L'Est de l'Île de Montréal | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03913026 ↗ |
| Modality | Cell therapy | “infused with 7-day UM171-expanded CD34+ cells” PMID 39419177 ↗ Oct 2024 |